MedTrace Logo

The Effects of Dragon Fruit Consumption on Vascular Function.

NCT03995602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-06-07

No results posted yet for this study

Summary

Native to South America and South East Asia, the dragon fruit (pitaya) has become increasingly popular world-wide due to their vivid hue and bizarre structure. More importantly, their high levels of bioactive phytochemical betalains has sparked considerable scientific interest. Recent findings from in vitro and in vivo animal studies tentatively suggest that betalains may have ameliorative effects on vascular function. This will be a first randomised controlled trial aimed to explore the impact of dragon fruit consumption on blood pressure and other vascular parameters in healthy individuals. The study will feature a randomised, double-blinded, placebo-controlled and crossover design with flow-mediated dilatation (FMD) as primary outcome along with blood pressure and arterial stiffness as secondary outcomes. Cardiovascular biomarkers as well as relevant metabolites will also be determined from blood and urine samples collected from participants.

Conditions

  • Healthy Men and Women

Interventions

DIETARY_SUPPLEMENT

Dragon fruit juice drink

Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.

DIETARY_SUPPLEMENT

Placebo

Drink with macro- and micro-nutrient matched against the intervention drink.

Sponsors & Collaborators

Principal Investigators

  • Ana Rodriguez-Mateos, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2020-01-22
Completion
2020-01-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03995602 on ClinicalTrials.gov